ArticleNeuro-oncology2017
Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
Article in Neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?Neuro-oncology · 2018Pooled it
- Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.Cells · 2026Review
- Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.Neuro-oncology · 2025Review
- Identifying appropriate external control datasets in support of future glioblastoma clinical trials leveraging external data.Neuro-oncology · 2025Article
- Design and conduct of theranostic trials in neuro-oncology: Challenges and opportunities.Neuro-oncology · 2024Review
- Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils.Neuro-oncology · 2024Review
- Clinical trials that leverage external data: Do we need more transparent protocols and statistical plans?European journal of cancer (Oxford, England : 1990) · 2024Article
- A critical analysis of neuro-oncology clinical trials.Neuro-oncology · 2023Article
- Using historical objective response rates to design single-arm phase II trials in patients with recurrent glioblastoma.Neuro-oncology · 2023Article
- Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.The Lancet. Oncology · 2023Review
- Bayesian Nonparametric Common Atoms Regression for Generating Synthetic Controls in Clinical Trials.Journal of the American Statistical Association · 2023Article
- Novel Clinical Trial Designs in Neuro-Oncology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Next Steps for Immunotherapy in Glioblastoma.Cancers · 2022Review
- Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- External controls to improve on glioblastoma clinical trials.Neuro-oncology · 2022Article
- An Overview of Phase 2 Clinical Trial Designs.International journal of radiation oncology, biology, physics · 2022Review
- Leveraging external data in the design and analysis of clinical trials in neuro-oncology.The Lancet. Oncology · 2021Review
- Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress.Frontiers in oncology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.